Quarterly report pursuant to Section 13 or 15(d)

ROYALTY OBLIGATIONS NET (Details Narrative)

v3.22.1
ROYALTY OBLIGATIONS NET (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Jan. 03, 2022
Mar. 31, 2022
Dec. 31, 2021
Interest expense amortization   $ 115,334 $ 115,334
Non-cash interest expense   $ 7,171,200  
Common stock shares issued, descripiton   the other one was with the J and R Galligan Revocable Trust, managed by Mr. Galligan, a holder of between 10% and 15% of the Company’s shares of common stock  
Expected life of the arrangement   15 years  
Royalty agreements description   Each party would purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), in the aggregate amount of $3,000,000 at a purchase price of $15.00 per share (the “Purchase Price”), for a total of 200,000 shares of Common Stock; and (ii) the Company shall pay each (a) a total of $37.50 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the first (1st) day that the first unit of the treatment is sold (the “Initial Sales Date”) and ending on the third (3rd) anniversary of the Initial Sales Date; and (b) a total of $25.00 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the day following the third (3rd) anniversary of the Initial Sales Date and ending on the fifteenth (15th) anniversary of the Initial Sales Date (the “Royalty”)  
Ownership percentage   50.00%  
Maximum [Member] | Joseph Galligan [Member]      
Ownership percentage 15.00% 15.00%  
Minimum [Member] | Joseph Galligan [Member]      
Ownership percentage 10.00% 10.00%